Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001281|
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : August 9, 2022
This study will examine the effects of HIV infection on substances produced by immune cells that increase or decrease HIV infection.
HIV-infected patients and healthy normal volunteers may be eligible for this study. Participants will be required to have a yearly medical evaluation, including blood tests for cell counts and chemistries, a blood or urine pregnancy test for women, and other laboratory tests as medically indicated or for research purposes.
Participants will donate blood or reproductive fluids, or both. From 20 to 150 cc (4 to 30 teaspoonfuls) of blood will be drawn from the arm using a small needle. Participants may be asked to provide blood samples on more than one occasion over the course of the study. No more than 450 cc (less than 1 pint) of blood will be drawn during any 6-week period. Males will be given a private room for semen donation; fluid from females will be collected with a cotton swab after speculum insertion. Participants may also be asked to have a buccal swab. For this procedure, the inside of the cheek is gently scraped with a blunt-ended stick or brush to obtain cells (buccal mucosal cells). The tissues will be used for a variety of studies on the effects of HIV infection on factors that increase or decrease HIV infection.
Some of the tissues collected for this study may also be used for the following tests:
- Hepatitis screening Blood may be screened for different types of viral liver infections, such as hepatitis A, B, C, D, E, or G.
- Genetic testing DNA from blood or cheek cells may be examined for mutations or deletions that affect chemokines, cytokines and a family of enzymes called caspases. Chemokines and cytokines are important mediators of the immune response. Alterations in the genes for some of these substances influence HIV infection. Caspases regulate the process of cell death, known as apoptosis. Caspase gene variations may determine the rate of cell death in HIV-infected persons, and therefore, the rate of HIV progression. Patients with abnormalities of any of these genes may be invited to join other studies of the role of genetic defects in HIV infection.
- HLA testing Blood may be tested for HLA type a genetic marker of the immune system. These tests may be used to try to identify factors associated with the rate of progression of HIV disease or related conditions. Determining HLA type is necessary to be able to perform certain research studies. Some HLA types have been associated with an increased risk of certain diseases like arthritis and other rheumatologic problems.
|Condition or disease|
|HIV Immunodeficiencies Infectious Diseases|
|Study Type :||Observational|
|Estimated Enrollment :||2600 participants|
|Official Title:||Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in HIV-Infected and HIV-Uninfected Volunteers|
|Actual Study Start Date :||March 9, 1993|
HIV Infected Individuals
HIV infected Individuals
HIV Uninfected Individuals
HIV uninfected Individuals
Individuals with/without Immunodeficiencies
Individuals with/without immunodeficiencies
Individuals with/without infectious diseases
Individuals with/without infectious diseases of interest
- The purpose of this protocol is to provide a mechanism to obtain blood products and other biologic samples that will be used by NIH Intramural Investigators in studies of HIV and other infectious or immune deficiency diseases [ Time Frame: Throughout ]To provide a mechanism to obtain blood products and other biologic samples that will be used by NIH Intramural Investigators in studies of HIV and other infectious or immune deficiency diseases.
- To provide the opportunity to compare genomic and proteomic properties of specimens obtained from individuals with HIV , other infectious diseases, and other immunodeficiencies with those of healthy volunteers [ Time Frame: Throughout ]To provide the opportunity to compare genomic and proteomic properties of specimens obtained from individuals with HIV, other infectious diseases, and other immunodeficiencies with those of healthy volunteers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001281
|Contact: Catherine A Seamon, R.N.||(301) email@example.com|
|Contact: Susan Moir, Ph.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY dial 711 email@example.com|
|Principal Investigator:||Susan Moir, Ph.D.||National Institute of Allergy and Infectious Diseases (NIAID)|